Data / Public companies / SIC 2836: Biological products, (no diagnostic substances) / Twist Bioscience Corp
Twist Bioscience Corp: revenue, net income and total assets from its latest annual report
Twist Bioscience Corp reported revenue of $376.6 million, a net loss of $77.7 million and total assets of $641.9 million for the fiscal year ended September 30, 2025, in its annual report (10-K) filed with the SEC on November 17, 2025. It ranks 17th by revenue of 89 companies in SIC 2836, biological products, (no diagnostic substances).
SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.
- SEC central index key (CIK)
- 1581280
- Industry
- SIC 2836, Biological products, (no diagnostic substances)
- Business address (city and state)
- South San Francisco, California
- Incorporated in
- Delaware
- Filer category
- Large accelerated filer
- Fiscal year ends
- September 30
- Latest annual report
- 10-K filed November 17, 2025
- Annual and quarterly reports in the data
- 1 annual, 4 quarterly
Financials for the fiscal year ended September 30, 2025
As filed, in US dollars. The prior year value is the comparison column in the same report.
| Item | This year | Prior year | Change | Source |
|---|---|---|---|---|
| Revenue | $376,572,000 | $312,974,000 | 20.3% | sec.gov |
| Operating income | $-136,259,000 | Not listed | Not listed | sec.gov |
| Net income | $-77,670,000 | $-208,726,000 | 62.8% | sec.gov |
| Total assets | $641,861,000 | $614,323,000 | 4.5% | sec.gov |
| Total liabilities | $168,903,000 | Not listed | Not listed | sec.gov |
| Stockholders' equity | $472,958,000 | Not listed | Not listed | sec.gov |
| Cash and cash equivalents | $183,049,000 | Not listed | Not listed | sec.gov |
How it compares
- Net margin (net income over revenue)
- -20.6%
- Revenue change on the prior year
- 20.3%
- Revenue rank in SIC 2836
- 17th of 89
- Revenue rank in California
- 313th of 662
- Revenue rank among all companies in the data
- 2,258th of 4,486
Companies next to it by revenue in SIC 2836
Biological products, (no diagnostic substances), from the same data.
| Company | Business address | Revenue | Net income | Total assets | Revenue change |
|---|---|---|---|---|---|
| Adma Biologics, Inc. | Ramsey, NJ | $510.2 million | $146.9 million | $624.2 million | 19.6% |
| Tarsus Pharmaceuticals, Inc. | Irvine, CA | $451.4 million | $-66,418,000 | $562.2 million | 146.7% |
| Immunocore Holdings PLC | Oxfordshire, United Kingdom | $400 million | $-35,514,000 | $1.07 billion | 29% |
| Krystal Biotech, Inc. | Pittsburgh, PA | $389.1 million | $204.8 million | $1.33 billion | 33.9% |
| Adaptive Biotechnologies Corp | Seattle, WA | $277 million | $-59,499,000 | $512.7 million | 54.8% |
| Vericel Corp | Cambridge, MA | $276.3 million | $16.5 million | $488 million | 16.5% |
| Iovance Biotherapeutics, Inc. | San Carlos, CA | $263.5 million | $-390,978,000 | $913.2 million | 60.6% |
| Vaxart, Inc. | South San Francisco, CA | $237.3 million | $16.3 million | $186.1 million | 726.7% |
Updated November 17, 2025. Read from SEC Financial Statement Data Sets, filing 0001581280-25-000025. Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.